Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ReCode Therapeutics
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia
June 27, 2024
From
ReCode Therapeutics
Via
Business Wire
New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction
June 13, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors
May 13, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in May Conferences
May 01, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis
February 21, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in February Conferences
February 20, 2024
From
ReCode Therapeutics
Via
Business Wire
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
February 15, 2024
From
ReCode Therapeutics
Via
Business Wire
Tickers
NTLA
ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia
January 03, 2024
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in November Conferences
November 10, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Closing of Extension to Series B Financing
September 19, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at September Investor Conferences
September 07, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs
July 10, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Jefferies Healthcare Conference
June 02, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development
April 17, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
March 27, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines
March 21, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia
March 15, 2023
From
ReCode Therapeutics
Via
Business Wire
Recode Therapeutics Expands Leadership Team with Appointment of April Loui as Senior Vice President of Quality and CMC Regulatory Affairs
February 01, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy
January 10, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform
January 09, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Appoints Trisha Millican to Board of Directors
December 01, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Upcoming Investor Conferences in 2022
November 22, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics Establishes Scientific Advisory Board
November 14, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in Upcoming November Investor Conferences
November 02, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in Upcoming October Investor Conferences
September 29, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit
September 22, 2022
From
ReCode Therapeutics
Via
Business Wire
Fierce Biotech Names ReCode Therapeutics as One of its “Fierce 15” Biotech Companies of 2022
September 12, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
ReCode Therapeutics
Via
Business Wire
ReCode Therapeutics to Participate in Upcoming July Investor Conferences
July 06, 2022
From
ReCode Therapeutics
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.